Please use this identifier to cite or link to this item:
Title: Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.
Austin Authors: McClure, Tess ;Cui, Wanyuan;Asadi, Khashayar ;John, Thomas ;Testro, Adam G 
Affiliation: Gastroenterology and Hepatology
Anatomical Pathology
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Medicine, The University of Melbourne, Melbourne, Victoria, Australia
Medicine (University of Melbourne)
Issue Date: Sep-2020
Date: 2020-09
Publication information: BMJ Open Gastroenterology 2020; 7(1): e000487
Abstract: Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined diagnostic criteria. Moreover, data regarding long-term outcomes are particularly lacking. We present a biopsy-proven case of nivolumab-induced sclerosing cholangitis, which uniquely captures 18 months of follow-up post-treatment. Our case highlights key features of intrahepatic subtype sclerosing cholangitis and suggests durable response to corticosteroid therapy.
DOI: 10.1136/bmjgast-2020-000487
ORCID: 0000-0003-2810-7443
Journal: BMJ Open Gastroenterology
PubMed URL: 32912846
ISSN: 2054-4774
Type: Journal Article
Subjects: autoimmune biliary disease
cancer immunobiology
cholestatic liver diseases
drug toxicity
liver function test
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jul 20, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.